TY - JOUR
T1 - Recent developments in the management of severe asthma
AU - Meteran, Howraman
AU - Tønnesen, Louise Lindhardt
AU - Sivapalan, Pradeesh
AU - Ingebrigtsen, Truls Sylvan
AU - Jensen, Jens Ulrik Stæhr
PY - 2022/3
Y1 - 2022/3
N2 - Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4.
AB - Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4.
UR - http://www.scopus.com/inward/record.url?scp=85130756860&partnerID=8YFLogxK
U2 - 10.1183/20734735.0178-2021
DO - 10.1183/20734735.0178-2021
M3 - Journal article
C2 - 36338257
AN - SCOPUS:85130756860
SN - 1810-6838
VL - 18
SP - 210178
JO - Breathe
JF - Breathe
IS - 1
M1 - 210178
ER -